Risk factors

Neuphoria Therapeutics (NEUP) risk factors

Item 1A of every Neuphoria Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open NEUP in Gloom →
Neuphoria Therapeutics' chart, financials and news, free in your browser.Open NEUP in Gloom →
  • FY2026 10-K risk factors
    117 risks26 new9 dropped23 reworded

    A $5.4 million goodwill impairment followed setbacks involving out-licensed assets and could recur if partners suspend development.

    Filed Sep 18, 2026
  • FY2025 10-K risk factors
    100 risks28 new16 dropped26 reworded

    Neuphoria Therapeutics relies heavily on clinical success, particularly for lead product candidate BNC210, and continued external financing.

    Filed Sep 29, 2025
  • FY2024 10-K risk factors
    88 risks

    Neuphoria Therapeutics faces typical clinical-stage biotechnology risks centered on cash burn, clinical trial execution, regulatory approval, and third-party manufacturing dependencies.

    Filed Sep 30, 2024